

Considered
8/7 7/18/06

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/691,033
Applicant : Zongqin Xia, et al.
Filed : October 21, 2003
Art Unit : 1654
Examiner : Susan D. Coe
Title : SMILAGENIN AND ITS USE

Docket No.: : HASEL-65949
Customer No. : 24201

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

I, Daryl Rees, hereby declare as follows:

1. This Declaration supplements the Declaration I have previously provided in this matter.
2. This Declaration relates to the objections raised in the Office Action dated 29 August 2005, which I have reviewed, and the matters discussed at the interview that I attended with Examiner Coe on March 8, 2006.
3. In the Office Action dated 29 August 2005, Examiner Coe argued that, while *in vitro* cell cultures and rat models "may be effective for screening possible anti-Parkinson's candidates, these models are not necessarily predicative of results in human patients".
4. Examiner Coe further argued that:

"the art teaches that effective treatment of Parkinson's disease in rat models does not necessarily predict successful treatment in humans due